Nexalin Technology, Inc.

Contributing Author

Recent Articles by Nexalin Technology, Inc.

May-21	Nexalin Technology Secures Key Neurostimulation Legislative Provision & Commends U.S. House-Passed Report Language Expanding Non-Invasive Deep Brain Neurostimulation Research at the Department of Veterans Affairs for Traumatic Brain Injury NXL +19.10% GlobeNewswire
May-19	Nexalin Acquires AI-Integrated Digital Health Platform Behind HALO Clarity and Nexalin NeuroCare Ahead of Planned FDA Pivotal Trial NXL GlobeNewswire
Apr-28	Nexalin Announces Peer-Reviewed Publication with Neuroimaging Data in Psychotherapy and Psychosomatics Highlighting Brain-Network Effects and Clinical Improvement in Chronic Insomnia NXL -8.62% GlobeNewswire
Apr-22	Nexalin Technology Advances Pivotal Clinical Trial of HALO Clarity Toward Q2 2026 Enrollment NXL +7.68% GlobeNewswire
Apr-15	Nexalin Advances FDA Alzheimer's Strategy Following Landmark Leadership Meetings in the U.S. and China NXL +18.43% GlobeNewswire
Apr-14	Join Nexalin's Exclusive Live Investor Webinar and Q&A Session on April 21 NXL GlobeNewswire
Apr-09	Nexalin Announces Peer-Reviewed Study Showing the Company's DIFS Technology Reduced Self-Injury and Depression Symptoms in Female Adolescents NXL +8.57% GlobeNewswire
Feb-24	Nexalin Announces Pivotal HALO Clarity Trial to Support Planned De Novo FDA Submission Targeting Multi-Billion-Dollar Insomnia Market NXL +15.06% GlobeNewswire
Feb-23	Nexalin Participates in and Commends Recent Congressional Momentum Supporting Deep Brain Neurostimulation Research for Veterans and Neurological Disorders NXL GlobeNewswire
Feb-05	Nexalin Launches NeuroCare, an AI-Driven Virtual Clinic Designed to Transform Access for Patients with Alzheimer's, Mood Disorders, TBI & PTSD Care NXL +9.15% GlobeNewswire
Feb-02	Nexalin Highlights its Expanding Body of Peer-Reviewed Neuroimaging Research Confirming its DIFS Technology as the Leader in Evidenced-Based Non-Invasive Brain Stimulation NXL GlobeNewswire
Jan-23	Nexalin Technology Receives Nasdaq Listing Status Notification NXL GlobeNewswire
Jan-14	Published Peer-Reviewed Study Demonstrates Nexalin's DIFS Neurostimulation Improves Attention and Normalizes Brain Activity in Patients with ADHD NXL +8.12% GlobeNewswire
Dec-03	Nexalin Technology Completes FDA Q-Submission Meeting for Gen-2 SYNC Neurostimulation Console in Alzheimer's Disease Program NXL GlobeNewswire
Dec-02	Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on December 4 NXL +5.43% GlobeNewswire
Nov-18	Nexalin's 15 Milliamp Neurostimulation Device Demonstrates Promising Results in Treating Gambling Disorder with Alcohol Use Comorbidity NXL GlobeNewswire
Nov-13	Nexalin Technology Appoints Carmi Masha Technologies Ltd. as Exclusive Distributor in Israel NXL -7.14% GlobeNewswire
Nov-05	Nexalin Technology's Q-Submission for Gen-2 SYNC Accepted by U.S. FDA for the Treatment of Alzheimer's Disease and Dementia NXL GlobeNewswire
Oct-30	Nexalin Technology Announces Regulatory Approval to Sell Gen 2 SYNC, 15 mA Neurostimulation DIFS Device in Israel NXL GlobeNewswire
Oct-21	Nexalin's DIFS Neurostimulation Shows Cognitive and Brain Network Improvements in Alzheimer's and Dementia Across Three Peer-Reviewed Studies NXL -8.33% GlobeNewswire
Oct-13	Nexalin Technology Expands Scientific Advisory Board with Appointment of Dr. Robert Rothstein to Support Alzheimer's and Traumatic Brain Injury Programs NXL GlobeNewswire
Oct-10	Nexalin Technology Announces Attendance at the 2025 Maxim Growth Summit NXL -14.67% GlobeNewswire
Oct-08	Nexalin Technology Announces Additional Positive Clinical Results in Alzheimer's Disease with Gen-2 SYNC Neurostimulation Device NXL +98.25% GlobeNewswire
Sep-25	Nexalin Technology Announces Issuance of U.S. Patent Covering HALO Clarity Device Featuring DIFS Technology NXL -6.05% GlobeNewswire
Aug-25	Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on September 9 NXL -18.24% GlobeNewswire
Aug-01	Nexalin Technology Appoints Highly Experienced Financial Leader Justin Van Fleet as CFO to Support Nexalin's Next Phase of Growth and Strategic Initiatives NXL GlobeNewswire
May-28	Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on June 3 NXL GlobeNewswire
May-13	Nexalin Technology Reconstitutes Scientific Advisory Board with Leading Experts to Advance Alzheimer's Program Amid Encouraging Data NXL GlobeNewswire
May-06	Nexalin Technology Announces Closing of Previously Announced $5.0 Million Underwritten Public Offering NXL -5.26% GlobeNewswire
May-05	Nexalin Technology Announces Pricing of $5.0 Million Public Offering of Common Stock NXL -25.70% GlobeNewswire
May-01	Nexalin Technology Initiates FDA Q-Submission Process for Gen-2 SYNC Following Encouraging Data and Preliminary FDA Feedback NXL GlobeNewswire

Nexalin Technology, Inc.

Recent Articles by Nexalin Technology, Inc.

Upgrade your Finviz experience